On September 7, 2021 Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, reported that Jonathan Drachman, M.D., Chief Executive Officer, will present a corporate overview during the H.C. Wainwright 23RD Annual Global Life Sciences Conference taking place September 13-15, 2021 (Press release, Neoleukin Therapeutics, SEP 7, 2021, View Source [SID1234587361]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A pre-recorded presentation will be available for on-demand access beginning at 7:00 am ET on Monday, September 13, 2021 from the investors section of the Neoleukin website at View Source An archived replay will also be available on the company website for at least 30 days following the event.

On September 7, 2021 Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics and Triclonics), reported that Bill Lundberg, M.D., Chief Executive Officer of Merus, will participate in the following investor conferences (Press release, Merus, SEP 7, 2021, View Source [SID1234587360]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Citi’s 16th Annual BioPharma Virtual Conference (Panel discussion): Thursday, Sept. 9, 2021 at 1:25-2:25 p.m. ET
H.C. Wainwright 23rd Annual Global Investment Conference (Presentation): Pre-recorded and available starting September 13 at 7:00 a.m. ET
2021 Cantor Virtual Global Healthcare (Presentation): Monday, September 27, 2021 at 2:40-3:10 p.m. ET
The webcast of the presentations will be available on the Investors page of the Company’s website. Archived presentations will also be available there for a limited time after the event.

On September 7, 2021 Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a cure for people with chronic hepatitis B virus (HBV) infection, as well as therapies to treat coronaviruses (including COVID-19), reported that the Company will participate in the following upcoming virtual investor conferences (Press release, Arbutus Biopharma, SEP 7, 2021, View Source [SID1234587359]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

H.C. Wainwright 23rd Annual Global Investment Conference (September 13-15, 2021)

Fireside Chat: available starting at 7:00 am ET on Monday, September 13, 2021
Presenters: William Collier, President and Chief Executive Officer; Dr. Michael Sofia, Chief Scientific Officer; Dr. Gaston Picchio, Chief Development Officer; and David Hastings, Chief Financial Officer
Webcast Link
Cantor Global Healthcare Conference (September 27-30, 2021)

Formal Presentation: Thursday, September 30, 2021 at 8:40 am ET
Presenter: William Collier, President and Chief Executive Officer
Webcast Link
The webcast links can also be accessed through the Investors section of Arbutus’ website at www.arbutusbio.com. An archived replay of the webcast will be available on the Company’s website after the conference.

On September 7, 2021 Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) ("Checkmate"), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, reported that Barry Labinger, CEO, will present at the H.C. Wainwright 23rd Annual Global Investment Conference (Press release, Checkmate Pharmaceuticals, SEP 7, 2021, View Source [SID1234587358]). The pre-recorded webcast will be available on demand, starting on Monday, September 13, 2021 at 7:00am ET. Checkmate will also host 1×1 investor meetings during the conference.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On September 7, 2021 RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, reported it has received a new 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its proprietary RenovoCath Delivery System (Press release, Renovorx, SEP 7, 2021, View Source [SID1234587357]). The RenovoCath Delivery System is the device component of the Company’s initial product, RenovoGem. This drug/device combination used in RenovoRx’s Trans-Arterial Micro-Perfusion (RenovoTAMP) therapy platform is a dual-balloon infusion catheter delivering chemotherapy directly to tumors via arteries. This new design provides more targeted delivery of therapy which the Company believes can translate into more effective treatment with fewer side effects. RenovoRx received its initial 510(k) for the RenovoCath delivery system in 2014.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Our novel RenovoTAMP therapy platform isolates the region of disease enabling delivery of the optimal dose of targeted chemotherapy to the tumor location," said Shaun Bagai, Chief Executive Officer at RenovoRx. "We believe this new design cleared through the FDA 510(k) process will further improve RenovoTAMP’s targeted delivery. Our focus is maximizing patient survival while minimizing side effects for cancer patients."

RenovoTAMP is the Company’s novel therapy platform designed to deliver well-established chemotherapeutic agents for localized treatment of solid cancer tumors. It is under clinical investigation for increasing survival and improving quality of life. This platform technology may enable physicians to isolate the anatomy and micro-perfuse targeted tissue with small molecule chemotherapy.

As of August 15, 2021, the Phase 3 TIGeR-PaC clinical trial — a randomized study utilizing the RenovoTAMP platform to evaluate RenovoGem — reached 44 percent patient enrollment for the treatment of pancreatic cancer. TIGeR-PaC is currently enrolling locally advanced, pancreatic cancer patients. In clinical studies conducted to date, chemotherapy delivered with the RenovoTAMP platform was associated with more than half the patients living more than two years. Pancreatic cancer patients treated standard-of-care typically live 12 to 15 months after diagnosis.

The TIGeR-PaC study, which currently has approximately 30 active clinical sites, is expected to involve approximately 200 participants in the US and Europe. To learn more, visit View Source